OncoMatch/Clinical Trials/NCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Is NCT06767514 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Ivonescimab and Pembrolizumab for non-small cell lung cancer.
Treatment: Ivonescimab · Pembrolizumab — Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) high expression (tps >50%) (tps >50%)
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
No prior systemic treatment for metastatic NSCLC.
Cannot have received: any prior therapy for NSCLC in the metastatic setting
Has received any prior therapy for NSCLC in the metastatic setting.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Study Site · Chandler, Arizona
- Clinical Study Site · Phoenix, Arizona
- Clinical Study Site · Hot Springs, Arkansas
- Clinical Study Site · Cerritos, California
- Clinical Study Site · Glendale, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06767514 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 high expression (tps >50%) is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify